HMGA2 expression in the PC-3 prostate cancer cell line is autonomous of growth factor stimulation

Anticancer Research

Volumn 33, Issue 8, 2013, Pages 3069-3078

  Muller, Marietta Henrike ^a   Drieschner, Norbert ^a   Focken, Tim ^a   Bartnitzke, Sabine ^a   Winter, Nina ^a   Klemke, Markus ^a   Bullerdiek, Jorn ^a  

^a UNIVERSITY OF BREMEN   (Germany)

Author keywords

Growth factor; HMGA2 expression; PC 3 cell line; Proliferation; Prostate cancer

Indexed keywords

FIBROBLAST GROWTH FACTOR 1; GROWTH FACTOR; HIGH MOBILITY GROUP A2 PROTEIN; PLATELET DERIVED GROWTH FACTOR BB;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL STRAIN PC 3; CHROMOSOME 12; CHROMOSOME PREPARATION; CONTROLLED STUDY; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE LOCUS; GENE REARRANGEMENT; HUMAN; HUMAN CELL; MALE; METAPHASE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RNA ISOLATION; SPECTRAL KARYOTYPING;

GROWTH FACTOR; HMGA2 EXPRESSION; PC-3 CELL LINE; PROLIFERATION; PROSTATE CANCER;

CELL LINE, TUMOR; CELL PROLIFERATION; CYTOGENETIC ANALYSIS; FIBROBLAST GROWTH FACTOR 1; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC LOCI; HMGA2 PROTEIN; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-SIS;

EID: 84883297901     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Gattas GJ, Quade BJ, Nowak RA and Morton CC: HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. Genes Chromosomes Cancer 25(4): 316-322, 1999.
2. Rogalla P, Drechsler K, Frey G, Hennig Y, Helmke B, Bonk U and Bullerdiek J: HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol 149(3): 775-779, 1996.
3. Hirning-Folz U, Wilda M, Rippe V, Bullerdiek J and Hameister H: The expression pattern of the Hmgic gene during development. Genes Chromosomes Cancer 23(4): 350-357, 1998.
4. Kubo H, Shimizu M, Taya Y, Kawamoto T, Michida M, Kaneko E, Igarashi A, Nishimura M, Segoshi K, Shimazu Y, Tsuji K, Aoba T and Kato Y: Identification of mesenchymal stem cell (MSC)-transcription factors by microarray and knockdown analyses, and signature molecule-marked MSC in bone marrow by immunohistochemistry. Genes Cells 14(3): 407-424, 2009.
5. Nishino J, Kim I, Chada K and Morrison SJ: Hmga2 promotes neural stem cell self-renewal in young, but not old, mice by reducing p16Ink4a and p19Arf expression. Cell 135(2): 227-239, 2008.
6. Rommel B, Rogalla P, Jox A, Kalle CV, Kazmierczak B, Wolf J and Bullerdiek J: HMGI-C, a member of the high mobility group family of proteins, is expressed in hematopoietic stem cells and in leukemic cells. Leuk Lymphoma 26(5-6): 603-607, 1997.
7. Markowski DN, Helmke BM, Meyer F, von Ahsen I, Nimzyk R, Nolte I and Bullerdiek J: BMP4 increases expression of HMGA2 in mesenchymal stem cells. Cytokine 56(3): 811-816, 2011.
8. Ashar HR, Fejzo MS, Tkachenko A, Zhou X, Fletcher JA, Weremowicz S, Morton CC and Chada K: Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell 82(1): 57-65, 1995.
9. Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H and Van de Ven WJ: Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet 10(4): 436-444, 1995.
10. Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M, Goldmann T, Vollmer E and Bullerdiek J: HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog 46(7): 503-511, 2007.
11. Schoenberg Fejzo M, Ashar HR, Krauter KS, Powell WL, Rein MS, Weremowicz S, Yoon SJ, Kucherlapati RS, Chada K and Morton CC: Translocation breakpoints upstream of the HMGIC gene in uterine leiomyomata suggest dysregulation of this gene by a mechanism different from that in lipomas. Genes Chromosomes Cancer 17(1): 1-6, 1996.
12. Klemke M, Meyer A, Nezhad MH, Bartnitzke S, Drieschner N, Frantzen C, Schmidt EH, Belge G and Bullerdiek J: Overexpression of HMGA2 in uterine leiomyomas points to its general role for the pathogenesis of the disease. Genes Chromosomes Cancer 48(2): 171-178, 2009.
13. Berner JM, Meza-Zepeda LA, Kools PF, Forus A, Schoenmakers EF, Van de Ven WJ, Fodstad O and Myklebost O: HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas. Oncogene 14(24): 2935-2941, 1997.
14. Roijer E, Nordkvist A, Strom AK, Ryd W, Behrendt M, Bullerdiek J, Mark J and Stenman G: Translocation, deletion/amplification, and expression of HMGIC and MDM2 in a carcinoma ex pleomorphic adenoma. Am J Pathol 160(2): 433-440, 2002.
15. Watanabe S, Ueda Y, Akaboshi S, Hino Y, Sekita Y and Nakao M: HMGA2 maintains oncogenic RAS-induced epithelialmesenchymal transition in human pancreatic cancer cells. Am J Pathol 174(3): 854-868, 2009.
16. Wu J, Liu Z, Shao C, Gong Y, Hernando E, Lee P, Narita M, Muller W, Liu J and Wei JJ: HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res 71(2): 349-359, 2011.
17. Miyazawa J, Mitoro A, Kawashiri S, Chada KK and Imai K: Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res 64(6): 2024-2029, 2004.
18. Thuault S, Tan EJ, Peinado H, Cano A, Heldin CH and Moustakas A: HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to- mesenchymal transition. J Biol Chem 283(48): 33437-33446, 2008.
19. Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH and Moustakas A: Transforming growth factor-beta employs HMGA2 to elicit epithelial- mesenchymal transition. J Cell Biol 174(2): 175-183, 2006.
20. Zhou X, Benson KF, Ashar HR and Chada K: Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 376(6543): 771-774, 1995.
21. Ayoubi TA, Jansen E, Meulemans SM and Van de Ven WJ: Regulation of HMGIC expression: an architectural transcription factor involved in growth control and development. Oncogene 18(36): 5076-5087, 1999.
22. Lanahan A, Williams JB, Sanders LK and Nathans D: Growth factor-induced delayed early response genes. Mol Cell Biol 12(9): 3919-3929, 1992.
23. Bartuma H, Panagopoulos I, Collin A, Trombetta D, Domanski HA, Mandahl N and Mertens F: Expression levels of HMGA2 in adipocytic tumors correlate with morphologic and cytogenetic subgroups. Mol Cancer 8: 36, 2009.
24. Lee YS and Dutta A: The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 21(9): 1025-1030, 2007.
25. Mayr C, Hemann MT and Bartel DP: Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315(5818): 1576-1579, 2007.
26. Peng Y, Laser J, Shi G, Mittal K, Melamed J, Lee P and Wei JJ: Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res 6(4): 663-673, 2008.
27. Kazmierczak B, Meyer-Bolte K, Tran KH, Wockel W, Breightman I, Rosigkeit J, Bartnitzke S and Bullerdiek J: A high frequency of tumors with rearrangements of genes of the HMGI(Y) family in a series of 191 pulmonary chondroid hamartomas. Genes Chromosomes Cancer 26(2): 125-133, 1999.
28. Markowski DN, Bartnitzke S, Belge G, Drieschner N, Helmke BM and Bullerdiek J: Cell culture and senescence in uterine fibroids. Cancer Genet Cytogenet 202(1): 53-57, 2010.
29. Hauke S, Flohr AM, Rogalla P and Bullerdiek J: Sequencing of intron 3 of HMGA2 uncovers the existence of a novel exon. Genes Chromosomes Cancer 34(1): 17-23, 2002.
30. Cleynen I and Van de Ven WJ: The HMGA proteins: A myriad of functions (Review). Int J Oncol 32(2): 289-305, 2008.
31. Fusco A and Fedele M: Roles of HMGA proteins in cancer. Nat Rev Cancer 7(12): 899-910, 2007.
32. Piscuoglio S, Zlobec I, Pallante P, Sepe R, Esposito F, Zimmermann A, Diamantis I, Terracciano L, Fusco A and Karamitopoulou E: HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma. Histopathology 60(3): 397-404, 2012.
33. Rogalla P, Drechsler K, Kazmierczak B, Rippe V, Bonk U and Bullerdiek J: Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: Relationship to histologic grade. Mol Carcinog 19(3): 153-156, 1997.
34. Heim S, Mandahl N, Kristoffersson U, Mitelman F, Rooser B, Rydholm A and Willen H: Reciprocal translocation t(3;12) (q27;q13) in lipoma. Cancer Genet Cytogenet 23(4): 301-304, 1986.
35. Turc-Carel C, Dal Cin P, Rao U, Karakousis C and Sandberg AA: Cytogenetic studies of adipose tissue tumors. I. A benign lipoma with reciprocal translocation t(3;12)(q28;q14). Cancer Genet Cytogenet 23(4): 283-289, 1986.
36. Heim S, Nilbert M, Vanni R, Floderus UM, Mandahl N, Liedgren S, Lecca U and Mitelman F: A specific translocation, t(12;14)(q14-15;q23-24), characterizes a subgroup of uterine leiomyomas. Cancer Genet Cytogenet 32(1): 13-17, 1988.
37. Fedele M, Berlingieri MT, Scala S, Chiariotti L, Viglietto G, Rippel V, Bullerdiek J, Santoro M and Fusco A: Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts. Oncogene 17(4): 413-418, 1998.
38. Hennig Y, Wanschura S, Deichert U, Bartnitzke S and Bullerdiek J: Rearrangements of the high mobility group protein family genes and the molecular genetic origin of uterine leiomyomas and endometrial polyps. Mol Hum Reprod 2(4): 277-283, 1996.
39. Nilsson M, Mertens F, Hoglund M, Mandahl N and Panagopoulos I: Truncation and fusion of HMGA2 in lipomas with rearrangements of 5q32→q33 and 12q14→q15. Cytogenet Genome Res 112(1-2): 60-66, 2006.
40. Quade BJ, Weremowicz S, Neskey DM, Vanni R, Ladd C, Dal Cin P and Morton CC: Fusion transcripts involving HMGA2 are not a common molecular mechanism in uterine leiomyomata with rearrangements in 12q15. Cancer Res 63(6): 1351-1358, 2003.
41. Qi J, Rice SJ, Salzberg AC, Runkle EA, Liao J, Zander DS and Mu D: MiR-365 regulates lung cancer and developmental gene thyroid transcription factor 1. Cell Cycle 11(1): 177-186, 2012.
42. Zhu S, Deng S, Ma Q, Zhang T, Jia C, Zhuo D, Yang F, Wei J, Wang L, Dykxhoorn DM, Hare JM, Goldschmidt-Clermont PJ and Dong C: MicroRNA-10A* and MicroRNA-21 modulate endothelial progenitor cell senescence via suppressing highmobility group A2. Circ Res 112(1): 152-164, 2013.
43. Borrmann L, Wilkening S and Bullerdiek J: The expression of HMGA genes is regulated by their 3'UTR. Oncogene 20(33): 4537-4541, 2001.
44. Lee S, Jung JW, Park SB, Roh K, Lee SY, Kim JH, Kang SK and Kang KS: Histone deacetylase regulates high mobility group A2- targeting microRNAs in human cord blood-derived multipotent stem cell aging. Cell Mol Life Sci 68(2): 325-336, 2011.
45. Liu Z, Liu J, Segura MF, Shao C, Lee P, Gong Y, Hernando E and Wei JJ: MiR-182 overexpression in tumourigenesis of highgrade serous ovarian carcinoma. J Pathol 228(2): 204-215, 2012.
46. Borrmann L, Seebeck B, Rogalla P and Bullerdiek J: Human HMGA2 promoter is coregulated by a polymorphic dinucleotide (TC)-repeat. Oncogene 22(5): 756-760, 2003.
47. Hodge JC, K TC, Huyck KL, Somasundaram P, Panhuysen CI, Stewart EA and Morton CC: Uterine leiomyomata and decreased height: a common HMGA2 predisposition allele. Hum Genet 125(3): 257-263, 2009.
48. Winkler S, Murua Escobar H, Meyer B, Simon D, Eberle N, Baumgartner W, Loeschke S, Nolte I and Bullerdiek J: HMGA2 expression in a canine model of prostate cancer. Cancer Genet Cytogenet 177(2): 98-102, 2007.
49. Zhu C, Li J, Cheng G, Zhou H, Tao L, Cai H, Li P, Cao Q, Ju X, Meng X, Wang M, Zhang Z, Qin C, Hua L, Yin C and Shao P: miR-154 inhibits EMT by targeting HMGA2 in prostate cancer cells. Mol Cell Biochem 379(1-2): 69-75, 2013.
50. Zong Y, Huang J, Sankarasharma D, Morikawa T, Fukayama M, Epstein JI, Chada KK and Witte ON: Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling. Proc Natl Acad Sci USA 109(50): E3395-3404, 2012.
51. Diana F, Di Bernardo J, Sgarra R, Tessari MA, Rustighi A, Fusco A, Giancotti V and Manfioletti G: Differential HMGA expression and post-translational modifications in prostatic tumor cells. Int J Oncol 26(2): 515-520, 2005.
52. Richter A, Hauschild G, Murua Escobar H, Nolte I and Bullerdiek J: Application of High-Mobility-Group-A Proteins Increases the Proliferative Activity of Chondrocytes In Vitro. Tissue Eng Part A 15(3): 473-477, 2009.
53. Richter A, Lubbing M, Frank HG, Nolte I, Bullerdiek J and von Ahsen I: High-mobility group protein HMGA2-derived fragments stimulate the proliferation of chondrocytes and adipose tissuederived stem cells. Eur Cell Mater 21: 355-363, 2011.
54. Venkatesan N, Krishnakumar S, Deepa PR, Deepa M, Khetan V and Reddy MA: Molecular deregulation induced by silencing of the high mobility group protein A2 gene in retinoblastoma cells. Mol Vis 18: 2420-2437, 2012.
55. Yu KR, Park SB, Jung JW, Seo MS, Hong IS, Kim HS, Seo Y, Kang TW, Lee JY, Kurtz A and Kang KS: HMGA2 regulates the in vitro aging and proliferation of human umbilical cord bloodderived stromal cells through the mTOR/p70S6K signaling pathway. Stem Cell Res 10(2): 156-165, 2012.
56. Wang YY, Ren T, Cai YY and He XY: MicroRNA let-7a inhibits the proliferation and invasion of nonsmall cell lung cancer cell line 95D by regulating K-Ras and HMGA2 gene expression. Cancer Biother Radiopharm 28(2): 131-137, 2013.
57. Kwabi-Addo B, Ozen M and Ittmann M: The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 11(4): 709-724, 2004.
58. Payson RA, Chotani MA and Chiu IM: Regulation of a promoter of the fibroblast growth factor 1 gene in prostate and breast cancer cells. J Steroid Biochem Mol Biol 66(3): 93-103, 1998.
59. Ittman M and Mansukhani A: Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate. J Urol 157(1): 351-356, 1997.
60. Dorkin TJ, Robinson MC, Marsh C, Neal DE and Leung HY: aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8. J Pathol 189(4): 564-569, 1999.
61. Nazarova N, Golovko O, Blauer M and Tuohimaa P: Calcitriol inhibits growth response to Platelet-Derived Growth Factor-BB in human prostate cells. J Steroid Biochem Mol Biol 94(1-3): 189-196, 2005.
62. Cheng J, Ye H, Liu Z, Xu C, Zhang Z, Liu Y and Sun Y: Plateletderived growth factor-BB accelerates prostate cancer growth by promoting the proliferation of mesenchymal stem cells. J Cell Biochem 114(7): 1510-1518, 2013.